健康对照与帕金森病患者的[18F]MFBG PET/CT心肌交感神经支配显像:剂量学与药代动力学
研究评估[18F]MFBG PET在健康对照和帕金森病患者中的剂量学与心肌药代动力学,3例对照全身扫描示平均有效剂量23.1±2.6 μSv/MBq。5例对照和3例PD患者行动态心脏PET/CT及[123I]MIBG SPECT/CT,对照组心肌分布容积VT为35.1±10.6 mL/cm3,PD组为5.9±1.6 mL/cm3。30分钟动态数据与120分钟数据的2TCM VT高度一致,结论认为[18F]MFBG PET是可行且安全的简化定量心肌交感神经支配的显像方法。
要点
- 健康对照心肌[18F]MFBG VT为35.1±10.6 mL/cm3,PD患者为5.9±1.6 mL/cm3。
- 30分钟动态PET的2TCM VT与120分钟数据高度一致(平均差-1.3 mL/cm3,R2=0.97)。
- [18F]MFBG平均有效剂量为23.1±2.6 μSv/MBq。
核心结论
- [18F]MFBG PET是可行且安全的显像方法,可用于无创且简化的心肌交感神经支配定量。
研究设计与样本
- 剂量学部分:3例对照接受注射后最长6小时的序贯全身[18F]MFBG PET/CT。
- 动态显像部分:5例对照和3例PD患者接受120分钟动态心脏[18F]MFBG PET/CT,并于注射后15分钟和3-4小时接受两次静态[123I]MIBG SPECT/CT及平面闪烁显像。
主要发现
- 平均有效剂量为23.1±2.6 μSv/MBq。
- [18F]MFBG血液池清除和心脏摄取迅速,对照组VT为35.1±10.6 mL/cm3,PD组为5.9±1.6 mL/cm3。
- 从注射开始30分钟动态PET数据集的2TCM VT与完整120分钟数据集的2TCM VT高度一致(平均差-1.3 mL/cm3,一致性界限-7.1至4.5 mL/cm3)且相关(R2=0.97,p<0.001)。
- [18F]MFBG HMR与VT的相关性在注射后10-30分钟和100-120分钟时间间隔相同(ρ=0.88,p=0.007)。
- [123I]MIBG HMR在注射后3-4小时与[18F]MFBG VT的相关性(ρ=0.9,p<0.005)强于注射后15分钟(ρ=0.69,p=0.069)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cardiac noradrenergic denervation visualized by meta-[123I]iodobenzylguanidine ([123I]MIBG) imaging supports the diagnosis of Parkinson's disease (PD). Recently, meta-[18F] fluorobenzylguanidine ([18F]MFBG) PET demonstrated favorable imaging characteristics compared with [123I]MIBG scintigraphy for neuroendocrine tumors. We assessed [18F]MFBG dosimetry and myocardial pharmacokinetics in healthy controls and PD patients. METHODS: For dosimetry, three controls underwent sequential whole-body [18F]MFBG PET/CT up to 6 hours postinjection. Five controls and three PD patients underwent 120-min dynamic cardiac [18F]MFBG PET/CT and two static [123I]MIBG SPECT/CT scans with planar scintigraphy, at 15 min and 3-4 h postinjection. An aortic image-derived input function with population-based radiometabolite corrections was validated against arterial sampling to derive myocardial distribution volume (VT) using a 2-tissue compartment model (2TCM). [18F]MFBG VT was assessed for time-stability and compared to heart-to-mediastinum ratio (HMR) for [18F]MFBG and [123I]MIBG. RESULTS: Mean effective dose was 23.1±2.6 μSv/MBq. [18F]MFBG exhibited rapid blood pool clearance and cardiac uptake, with VT of 35.1±10.6 mL/cm3 in controls and 5.9±1.6 mL/cm3 in PD. 2TCM VT from 30-min dynamic PET datasets starting at tracer injection showed strong agreement (mean difference -1.3 mL/cm3 and LoA=-7.1 mL/cm3 to 4.5 mL/cm3) and correlation (R2=0.97, p<0.001) to 2TCM VT from full 120-min datasets. [18F]MFBG HMR correlated the same to [18F]MFBG VT (ρ=0.88, p=0.007) for 10-30-min as for 100-120-min postinjection time intervals. [123I]MIBG HMR correlated more strongly to [18F]MFBG VT at 3-4h (ρ=0.9, p<0.005) compared to at 15-min (ρ=0.69, p=0.069) postinjection. CONCLUSION: [18F]MFBG PET is a feasible and safe imaging modality for non-invasive and simplified quantification of myocardial sympathetic innervation. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov https://clinicaltrials.gov/study/NCT06120049.
引用
- Versweyveld L, Delva A, Cohilis M, et al. [18F]MFBG PET/CT imaging of myocardial sympathetic innervation in healthy controls and patients with parkinson's disease: dosimetry and pharmacokinetics. Eur J Nucl Med Mol Imaging. 2025. PMID: 40924149. doi:10.1007/s00259-025-07517-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。